DLST and cancer: CPI-613, an inhibitor targeting DLST/KGDHC in the TCA cycle, is in clinical trials for treating other types of cancers and shows promising safety and efficacy profiles (NCT03793140; NCT03699319; NCT04217317; and NCT04593758)30,31.